Kazumasa Jojima

Kitakyushu, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Real-world Outcomes of First-line Platinum-based Chemotherapy in Patients Aged 80 Years or Older With Metastatic Urothelial Carcinoma.

Real-world Outcomes of First-line Platinum-based Chemotherapy in Patients Aged 80 Years or Older With Metastatic Urothelial Carcinoma.

Journal: Cancer diagnosis & prognosis

Published: May 11, 2026

Recurrence of Low-risk Non-muscle-invasive Bladder Cancer in Patients Who Did Not Receive Immediate Intravesical Chemotherapy.

Recurrence of Low-risk Non-muscle-invasive Bladder Cancer in Patients Who Did Not Receive Immediate Intravesical Chemotherapy.

Journal: Cancer diagnosis & prognosis

Published: October 11, 2025

Immune Checkpoint Inhibitor Retreatment after Enfortumab Vedotin in Advanced Urothelial Carcinoma: A Descriptive Study with Exploratory Evaluation of Radiotherapy.

Immune Checkpoint Inhibitor Retreatment after Enfortumab Vedotin in Advanced Urothelial Carcinoma: A Descriptive Study with Exploratory Evaluation of Radiotherapy.

Journal: JMA journal

Published: September 22, 2025

Adjuvant Nivolumab Therapy for Upper Tract Urothelial Carcinoma: A Single-Institution Study.

Adjuvant Nivolumab Therapy for Upper Tract Urothelial Carcinoma: A Single-Institution Study.

Journal: Cureus

Published: August 11, 2025

Visfatin Promotes Renal Cell Carcinoma Progression: Evidence from Clinical Samples and Cell Line Models.

Visfatin Promotes Renal Cell Carcinoma Progression: Evidence from Clinical Samples and Cell Line Models.

Journal: Journal of kidney cancer and VHL

Published: June 25, 2025

Prostate-specific Antigen Decline During Primary Androgen-deprivation Therapy for Predicting Response and Survival in Metastatic Castration-resistant Prostate Cancer Patients Receiving Enzalutamide.

Prostate-specific Antigen Decline During Primary Androgen-deprivation Therapy for Predicting Response and Survival in Metastatic Castration-resistant Prostate Cancer Patients Receiving Enzalutamide.

Journal: In vivo (Athens, Greece)

Published: March 19, 2025

Survival and Safety Outcomes of Avelumab Maintenance Therapy for Advanced Urothelial Carcinoma from a Single-Center Experience.

Survival and Safety Outcomes of Avelumab Maintenance Therapy for Advanced Urothelial Carcinoma from a Single-Center Experience.

Journal: In vivo (Athens, Greece)

Published: February 15, 2025

Clinical significance of the dose modification of enfortumab vedotin monotherapy for advanced urothelial carcinoma.

Clinical significance of the dose modification of enfortumab vedotin monotherapy for advanced urothelial carcinoma.

Journal: Japanese journal of clinical oncology

Published: December 15, 2024

Clinical Outcomes of Micropapillary Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy.

Clinical Outcomes of Micropapillary Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy.

Journal: Cancer diagnosis & prognosis

Published: October 10, 2024

Initial-to-nadir Prostate-specific Antigen Ratio Predicts Response to First-line Enzalutamide in Metastatic Castration-resistant Prostate Cancer.

Initial-to-nadir Prostate-specific Antigen Ratio Predicts Response to First-line Enzalutamide in Metastatic Castration-resistant Prostate Cancer.

Journal: Anticancer research

Published: July 21, 2023

Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Early Experience in the Real World.

Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Early Experience in the Real World.

Journal: Anticancer research

Published: May 31, 2023

IMPACT OF ADJUVANT CHEMOTHERAPY AFTER RADICAL CYSTECTOMY FOR PATIENTS WITH LOCALLY ADVANCED BLADDER CANCER

IMPACT OF ADJUVANT CHEMOTHERAPY AFTER RADICAL CYSTECTOMY FOR PATIENTS WITH LOCALLY ADVANCED BLADDER CANCER

Journal: Nihon Hinyokika Gakkai zasshi. The japanese journal of urology

Published: January 01, 2023

Showing 1-12 of 12

Last Updated: 09/26/2026